Clinical Trials Browser

Phase 2/3 × Cystadenocarcinoma, Serous × Topotecan × Clear all

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Phase 2/3 Completed

260 enrolled 20 charts

Cystadenocarcinoma, Serous